The History of Terrorism
Preview
Open in TheBrain
Links
Categories by type
Types of Diseases
Infectious diseases
Infectious diseases by type of pathogen
Viral diseases
Animal viral diseases
Viral respiratory tract infections
Respiratory syncytial virus (RSV)
Jason McLellan
Attachments
wikipedia
Parents
2012-Today Golden Goose Award
Charles H. Hood Foundation Child Health Research Award
COVID-19 and spike protein links
COVID-19 University of Texas at Austin links
COVID-19 vaccine researchers
Crystallographic Association Etter Early Career Award
Norman P. Salzman Memorial Award in Virology
Respiratory syncytial virus (RSV)
University of Texas at Austin faculty
Viruses Young Investigator in Virology Prize
William Prusoff Memorial Award
Children
1963-Today Icahn School of Medicine at Mount Sinai (ISMMS)
2020 In May, 2020, he published a new version of the stabilized SARS-CoV-2 spike protein called HexaPro that is currently being used as the basis for a new vaccine, NDV-HXP-S, which is undergoing trials in Brazil, Mexico, Thailand and Vietnam.
2020 Jason McLellan and Daniel Wrapp received a 2020 Golden Goose Award for this research.
2020-2021 McLellan and his team worked with pharmaceutical company Eli Lilly and Company to develop their monoclonal antibody treatment bamlanivimab (LY-CoV555),[23] which received emergency use authorization from the U.S. Food and Drug Administration...
2020? In a separate but related project, McLellan and Daniel Wrapp worked with colleagues at the NIAID Vaccine Research Center and Ghent University to develop an antibody therapy for COVID-19 based on antibodies produced by a Winter (llama), a llama.
At least three other vaccines use this modified spike protein: those from Pfizer and BioNTech, Johnson & Johnson and Janssen Pharmaceutica, and Novavax.
Bamlanivimab ( LY-CoV555, LY3819253)
Daniel Wrapp
DS-Cav1 (RSV vaccine)
Emergent Biosolutions/Novavax/CEPI Novavax COVID-19 Vaccine (AKA Covovax, NVX-CoV2373, TAK-019, SARS-CoV-2 rS with Matrix-M1 adjuvant)
HexaPro
Janssen COVID-19 vaccine (AKA Ad26.COV2.S, JNJ-78436735, Ad26COVS, VAC31518)
McLellan-along with his team members Daniel Wrapp and Nianshuang Wang, plus Barney Graham and Kizzmekia Corbett at NIAID's Vaccine Research Center-engineered the spike protein to stay in its initial shape so it can be recognized.
McLellan, along with Barney S. Graham and Peter Kwong of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, spearheaded the development of a protein subunit vaccine against RSV called DS-Cav1.
NDV-HXP-S (AKA ButanVac, ADAPTCOV, COVIVAC, HXP-GPOVac, Patria)
NIAID, DARPA, BARDA, Lonza and Moderna's mRNA-1273 COVID-19 vaccine
Nianshuang Wang
Pfizer and BioNTech's COVID-19 BNT162b2 Vaccine (Comirnaty)
S-2P (2P)
The stabilized spike protein developed by McLellan and his colleagues forms the basis of three COVID-19 vaccines that received emergency use authorization in the U.S.
VHH72
Working alongside Jason McLellan, a structural biologist, they discovered that "adding two prolines to a key joint of a vaccine's spike protein could stabilize the structure's prefusion shape". Later, this method would be applied to the COVID-19 vaccine.
Jumps
1876-Today Eli Lilly and Company (NYSE: LLY)
1999-Today Vaccine Research Center (VRC AKA Dale and Betty Bumpers Vaccine Research Center)
Barney S. Graham
Kizzmekia Corbett
Peter Kwong